Clinical Trial Update: IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing IMC-F106C regimen versus nivolumab regimens in previously untreated advanced melanoma; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• IMC-F106C
• nivolumab (nivolumab)

Snippet

Sponsor: Immunocore Ltd | Conditions: Advanced Melanoma | Phase 3 | Status: RECRUITING